Waypoint Bio raises $20.0M (China, May 2026)
Find the investors funding Health rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China - Endpoints News
Waypoint Bio is a biotechnology company focused on developing innovative CAR-T therapies. The company aims to address unmet medical needs in cancer treatment through its clinical trials in China. This funding will support the execution of three CAR-T trials, highlighting the company's commitment to advancing cancer therapies.
Exclusive: Waypoint Bio raises $20M to run three CAR-T trials in China Endpoints News
| Sep 18, 2026 | Naive AI | $400.0M | — | China |
| Sep 17, 2026 | Jiuwanli Future Technology | $100.0M | — | China |
| Sep 14, 2026 | Guangyu Xinchen | $300.0M | Series A | China |
| Sep 10, 2026 | Qingyan Technology | $15.0M | Series A | China |
11,303 investors back startups in China
You just read who funded Waypoint Bio. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.